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Survival for Patients with Gallbladder Carcinoma1
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Masatoshi Makuuchi
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,
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ABSTRACT
This study was designed to test the hypothesis that
cyclin D1 overexpression is involved in the multistep process
of gallbladder carcinogenesis and can be used to predict
poor prognosis for patients with gallbladder carcinoma
(GBC). Cyclin D1 expression was examined immunohisto-
chemically in a series of specimens, including 8 normal
epithelia, 8 benign adenomyoma lesions, 6 precancerous
adenomas, and 37 carcinomas of the gallbladder. Four of the
6 (67%) adenomas and 15 of the 37 (41%) adenocarcinomas
demonstrated cyclin D1 overexpression (>5% nuclear stain-
ing), whereas all normal epithelia and adenomyoma lesions
were negative for cyclin D1. Kaplan-Meier curves showed
that cyclin D1 overexpression was significantly related to
decreased overall survival (P < 0.05) in patients with GBCs.
The Cox proportional hazards model identified cyclin D1
overexpression as an independent prognostic marker for
death (P 5 0.024; risk ratio, 4.2; 95% confidence interval,
1.2–14.7). To test whether cyclin D1 overexpression is a
critical event in gallbladder neoplasms, cyclin-dependent
kinase inhibitor p27Kip1 was introduced to ascertain how
cyclin D1 affects clinical outcomes. Subsequently, neoplasms
were divided into three groups on the basis of the combina-
tion of cyclin D1 expression and p27Kip1 status, which had
been determined previously. Group 1 showed no abnormal-
ity in either cyclin D1 or p27Kip1 expression. Group 2
showed aberrant expression of one of the two proteins,
whereas group 3 showed concurrent abnormalities in both
proteins. Results indicated that overall survival was greatest
in group 1, followed by a significant decrease in group 2 and
a more precipitous decrease in group 3. In conclusion, cyclin
D1 overexpression is an early event in gallbladder carcino-
genesis and independently predicts decreased survival for
patients with GBC.
INTRODUCTION
Multiple genetic or epigenetic changes contribute to the
multistep process of human carcinogenesis, and some of these
changes help with the monitoring of this multistep process. It is
important to understand the carcinogenic process and its corre-
sponding molecular basis for each type of cancer. For gallblad-
der carcinogenesis, the dysplasia to carcinoma and adenoma to
carcinoma conventional progressions have been generally ascer-
tained (1, 2). However, the molecular mechanism underlying the
development and progression of GBC3 is not fully understood.
This is possibly because of the relative rarity of GBC, which
accounts for only 3% of gastrointestinal cancers and 0.5% of all
human malignancies, limiting the number of tumor samples
available for study. GBC is one of the most biologically virulent
cancers and is difficult to cure by conventional procedures.
Elucidation of its molecular basis may be helpful in developing
and identifying prognostic biomarkers.
Escaping from normal cell cycle controls is critical for the
various processes of carcinogenesis (3–6). Cell cycle regulators
more often altered in cancers are those controlling G1-S-phase
progression. G1-S transition is controlled through interaction of
several types of molecules, including CDKs, their positive reg-
ulators, cyclins (cyclins D1, D2, D3, and E), and their negative
regulators, CDK inhibitors and retinoblastoma protein. CDK
inhibitors fall into two classes on the basis of their sequence
homology: (a) the INK family, which includes p16INK4,
p15INK4B, p18INK6A, and p19INK6B; and (b) the Cip/Kip family,
which includes p21WAF1/Cip1, p27Kip1, and p57Kip2. Among
these proteins controlling the G1-S transition, cyclin D1 is one
of the most strongly implicated in tumorigenesis. Cyclin D1
exerts its effects on cell cycle progression via two mechanisms:
(a) cyclin D1-CDK complexes inactivate retinoblastoma protein
by phosphorylation; and (b) these complexes bind and sequester
Cip/Kip proteins stoichiometrically (7). Evidence for the onco-
genic potential of cyclin D1 is provided by studies with numer-
ous models, in which elevated expression of cyclin D1 shortens
the G1 phase of the cell cycle and enhances malignant transfor-
mation (8–12).
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Cyclin D1 overexpression, either with or without gene
amplification, has been shown in a variety of human malignan-
cies, including breast (13–18), colon (19), lung (20), esophageal
(21–23), liver (24–26), pancreatic (27), tongue (28), oral ver-
rucous (29), pharyngeal (30), and laryngeal (31) cancers and has
been identified as a prognostic biomarker for breast (16), lung
(20), esophageal (22, 23), pancreatic (27), tongue (28), pharyn-
geal (30), and laryngeal (31) cancers. The role of cyclin D1 in
GBC has not been extensively studied. Recently, we showed
that cyclin D1 overexpression is significantly associated with
poor clinical outcomes for patients with extrahepatic bile duct
cancer (32), another type of biliary tract malignancy. Moreover,
cyclin D1 overexpression has been suggested to be an early
event in human breast (18), lung (33), and colon (34, 35)
carcinogenesis and in mouse skin carcinogenesis (36). On the
basis of this background, we postulated that cyclin D1 overex-
pression may be involved in the multistep process of gallbladder
carcinogenesis and may be useful as a prognostic marker for
GBC. To test this hypothesis, we attempted to study cyclin D1
expression using immunohistochemistry in a series of surgically
resected specimens, including normal epithelium, benign lesion
adenomyoma, adenoma, and adenocarcinoma of gallbladder
from patients treated surgically who had been in a postoperative
follow-up phase.
MATERIALS AND METHODS
Patients. Thirty-seven GBC lesions surgically resected
from 36 patients (one patient had two cancers) between January
1990 and April 1999 in our department were studied. There
were 17 males and 19 females, with a median age of 65 years
(age range, 45–84 years). The clinicopathological variables
were evaluated following the General Rules for Surgical and
Pathological Studies on Cancer of Biliary Tract of the Japanese
Society of Biliary Surgery (37). Cancers were staged following
the TNM system of the International Union against Cancer (38).
The clinicopathological features are described in Table 1. Sur-
gical procedures included 23 cholecystectomies (single chole-
cystectomy or cholecystectomy with resection of ,2 cm depth
of the liver bed) and 13 extended operations (resection of
adjacent organs in addition to the gallbladder). Four patients
who underwent palliative surgery were excluded from survival
analysis.
The status of p27Kip1 expression in this group of GBCs has
been studied previously (39). The 37 tumors were classified as
16 tumors with decreased p27Kip1 expression (,50% of tumor
cells showing nuclear p27Kip1 immunoreactivity), and 21 tumors
with normal p27Kip1expression ($50% of tumor cells showing
nuclear p27Kip1 immunoreactivity).
Six surgically resected specimens of gallbladder adenomas
were studied. None of the adenomas had foci of carcinoma in
situ. Eight specimens of adenomyoma, as well as eight speci-
mens of normal gallbladder epithelia obtained from healthy
persons who had undergone cholecystectomy when donating
partial livers for transplantation, were also included in this
study.
Immunohistochemistry. Five-mm-thick sections were
cut from formalin-fixed paraffin-embedded tissue blocks and
mounted on gelatin-coated glass slides. The sections were de-
waxed in xylene, rehydrated through graded concentrations of
ethanol, and then treated with 0.5% hydrogen peroxide at room
temperature for 30 min to block endogenous peroxidase activity.
The sections were immersed in 10 mM citrate buffer (pH 6.0)
and processed in an autoclave for 10 min at 120°C for antigen
retrieval (32, 40). Anti-cyclin D1 antibody (Clone DCS-6; Neo-
Markers, Union City, CA; dilution, 1:50) was applied, and
incubations were performed overnight at 4°C. Immunohisto-
chemistry was performed by the avidin-biotin complex tech-
nique using the Vectastain ABC Elite kit (Vector Laboratories,
Burlingame, CA) with 3,39-diaminobenzidine tetrahydrochlo-
ride development and hematoxylin counterstaining. Negative
controls were sections stained without the primary antibody.
Nuclear staining was considered to indicate specific cyclin D1
immunoreactivity.
Table 1 Clinicopathological features and Cyclin D1 expression in
gallbladder carcinomas
Factors Total no.
No. overexpressing
cyclin D1 (%)a
Age (yr)
#65 20 8 (40)
.65 17 7 (41)
Gender
Male 17 8 (47)
Female 20 7 (35)
Histological type
PAb 12 5 (42)
WDTA 12 6 (50)
MDTA 6 2 (33)
PDTA 3 2 (67)
Othersc 4 0
Vascular invasion
Yes 12 5 (42)
No 25 10 (40)
Lymphatic invasion
Yes 12 5 (42)
No 25 10 (40)
Perineural invasion
Yes 13 4 (31)
No 24 11 (46)
Lymph node involvement
Yes 12 3 (25)
No 25 12 (48)
Stage
I 11 7 (64)
II 11 4 (36)
III 7 1 (14)
IV 8 3 (38)
p27Kip1 expression
,50% 16 7 (44)
$50% 21 8 (38)
Surgical procedure
Cholecystectomyd 24 14 (58)
Extended operatione 13 8 (62)
a No comparisons reached the significant level (x2 test).
b PA, papillary adenocarcinoma; WDTA, well-differentiated tubu-
lar adenocarcinoma; MDTA, moderately differentiated tubular adeno-
carcinoma; PDTA, poorly differentiated tubular adenocarcinoma.
c Includes one mucinous adenocarcinoma, one signet ring cell
carcinoma, one adenosquamous cell carcinoma, and one undifferenti-
ated carcinoma.
d Single cholecystectomy or cholecystectomy with resection of less
than 2 cm depth of the liver bed.
e Resection of adjacent organs in addition to the gallbladder.
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For each case, one section having the greatest area of tumor
and one section containing noncancerous gallbladder epithelium
were selected for immunohistochemical staining from the tissue
blocks on the basis of observation of H&E-stained sections. The
scoring of cyclin D1 immunoreactivity was based on examina-
tion of 10 high-power (3400) microscopic fields or total tumor
(when tumor was smaller than 10 fields) for each case. Accord-
ing to a widely accepted criterion (17, 18, 23, 26, 30–32),
tumors that expressed strong immunoreactivity in .5% of the
cells were considered cyclin D1 positive (overexpression). All
slides were interpreted independently by two investigators (A-
M. H. and X. L.) without knowledge of the patients’ clinical
courses.
Statistical Analysis. The associations between cyclin D1
expression and clinicopathological variables were assessed us-
ing the x2 test. Survival curves were plotted using the Kaplan-
Meier method and compared using the log-rank test (41). The
significance of various parameters for survival was analyzed by
the Cox proportional hazards model (42). P , 0.05 was con-
sidered statistically significant.
RESULTS
Normal gallbladder epithelia from either healthy persons or
GBC patients were consistently negative with regard to cyclin
D1 nuclear immunoreactivity (Fig. 1A), demonstrating ,1%
positive cells. All eight adenomyoma lesions were also cyclin
D1 negative (Fig. 1B). For seven of these specimens, the per-
centage of positive epithelial cells was ,1%, and in the eighth
specimen cyclin D1 immunoreactivity was observed in 3% of
the epithelial cells. Four of the six (67%) adenomas showed
cyclin D1 overexpression (.5% positive cells; Fig. 1C) with the
percentage of positive cells ranging from 8% to 90%.
Twenty-two of the 37 GBCs were cyclin D1 negative
(59%; Fig. 1D), and the remaining 15 were cyclin D1 positive
(41%; Fig. 1E). For the 15 cyclin D1-positive cancers, the
percentage of cyclin D1-positive cells ranged from 6% to 90%.
Cyclin D1 expression was not related to any clinicopathological
parameters such as age, tumor histological type, lymphatic
metastasis, TNM stage, p27Kip1 expression status, or surgical
procedure (Table 1).
The duration of follow-up of the patients ranged from
Fig. 1 Examples of cyclin D1 immunohistochemical staining. Normal gallbladder epithelia (A) and an adenomyoma (B), both of which were cyclin
D1 negative. C, an adenoma demonstrating cyclin D1 overexpression. D, a cyclin D1-negative carcinoma. E, a carcinoma demonstrating cyclin D1
overexpression (3350).
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3–101 months (median follow-up, 28 months). The Kaplan-
Meier method and log-rank test were used to evaluate the effect
of cyclin D1 expression on postoperative survival in 32 patients
with GBCs, excluding four patients who underwent nonradical
surgery. The 3-year and 5-year overall survival rates were 68%
and 53% for all of the 32 patients. The corresponding figures
were 80% and 71% for the cyclin D1-negative group and 50%
and 30% for the cyclin D1-positive group, respectively. Cyclin
D1 overexpression significantly predicted reduced overall sur-
vival (Fig. 2; P , 0.05). Multivariate analysis by the Cox
proportional hazards model identified cyclin D1 overexpression
(P 5 0.024; risk ratio, 4.2; 95% confidence interval, 1.2–14.7),
decreased p27Kip1 expression (P 5 0.024; risk ratio, 4.2; 95%
confidence interval, 1.3–13.7), and TNM stage III/IV (P 5
0.001; risk ratio, 5.9; 95% confidence interval, 1.5–23.0) as
independent predictors of death. The 3-year and 5-year overall
survival rates were 84% and 71% for the patients who under-
went cholecystectomy and 40% and 0% for those treated by
extended operations. There was a significant difference between
the survival curves (P 5 0.007, log-rank test); however, the
surgical procedure had no significance as an independent prog-
nostic factor in the Cox proportional hazards model analysis.
The effect of surgical procedure on survival probably resulted
from the influence of disease stage; indeed, 9 of the 13 patients
who underwent extended operations had stage III or stage IV
tumors.
Drawing together the data of our present study and the
previous one (39), in which ,50% p27Kip1 nuclear staining was
defined as decreased p27Kip1 expression, GBCs were classified
into three groups on the basis of cyclin D1 and p27Kip1 expres-
sion: (a) group 1, no abnormality in either cyclin D1 or p27Kip1
expression (#5% cyclin D1 and $50% p27Kip1); (b) group 2,
altered expression of one of the two proteins (.5% cyclin D1
and $50% p27Kip1 or #5% cyclin D1 and ,50% p27Kip1); and
(c) group 3, concurrent abnormalities in both proteins (.5%
cyclin D1 and ,50% p27Kip1). Kaplan-Meier curves showed
that overall survival was significantly shorter in group 2 (n 5
14) than in group 1 (n 5 12) and was even shorter in group 3
[n 5 6; Fig. 3; group 1 versus group 2, P , 0.05; group 2 versus
group 3, P , 0.05; group 1 versus group 3, P , 0.01 (log-rank
test)]. The 3-year and 5-year overall survival rates were 100%
and 88% for group 1, 64% and 38% for group 2, and 17% and
17% for group 3.
DISCUSSION
The involvement of cyclin D1 overexpression has been
reported previously in a wide range of human cancers. To
determine the potential oncogenic role of cyclin D1 in human
gallbladder carcinogenesis, we designed the present study to
evaluate the levels of cyclin D1 expression in a series of surgi-
cally resected specimens including normal epithelia, adenomy-
oma lesions, precancerous adenomas, and adenocarcinomas of
the gallbladder. Cyclin D1 overexpression was frequently ob-
served in adenocarcinomas and even in adenomas, but not in any
specimen of normal epithelium or adenomyoma. This strongly
suggests that increased cyclin D1 expression is an early event in
gallbladder carcinogenesis, probably playing a critical role in
the transformation of gallbladder epithelial cells. Recently, cy-
clin D1 overexpression has also been observed in precursor
lesions for other types of cancers, including breast hyperplasia
(18), atypical adenomatous hyperplasia of the lung (33), and
adenomatous polyps of the colon (34, 35).
It is interesting to note that, in this study, the frequency of
cyclin D1 overexpression was higher in adenomas (67%) than in
cancers (41%). There are two possible interpretations for this
novel phenomenon: (a) in the process of gallbladder carcino-
genesis, cyclin D1 overexpression may only be needed for
establishment of the transformed phenotype, and in some cases
it may no longer be needed for maintenance of the transformed
Fig. 2 Kaplan-Meier curves for overall survival according to cyclin D1
expression in 32 patients who underwent radical surgery for GBC. Tick
marks indicate surviving patients and the duration of follow-up. P ,
0.05, log-rank test.
Fig. 3 Kaplan-Meier curves for overall survival according to the com-
bination of cyclin D1 and p27Kip1 expression in 32 patients who under-
went radical surgery for GBC. Tick marks indicate surviving patients
and the duration of follow-up. Group 1, no abnormality in either cyclin
D1 or p27Kip1 expression (#5% cyclin D1 and $50% p27Kip1); group 2,
aberrant expression of one of the two proteins (.5% cyclin D1 and
$50% p27Kip1 or #5% cyclin D1 and ,50% p27Kip1); group 3, coin-
cident abnormalities in the expression of both proteins (.5% cyclin D1
and ,50% p27Kip1). Group 1 versus group 2, P , 0.05; group 2 versus
group 3, P , 0.05; group 1 versus group 3, P , 0.01 (log-rank test).
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phenotype once the lesions have become malignant; and (b) the
dysplasia to carcinoma sequence, as well as the adenoma to
carcinoma progression, and other routes also contribute to the
development of GBCs. Overexpression of cyclin D1 may be
involved only in the adenoma to carcinoma route of gallbladder
carcinogenesis and may not be involved in other pathways.
The most important finding in this study is that accumula-
tion of cyclin D1 adversely affects clinical outcome and serves
as an independent marker predicting decreased survival for
patients with GBC. This is easy to understand, because cyclin
D1 shortens the G1 phase and accelerates the cell cycle (8). We
have recently found that deregulation of p27Kip1, another key
protein in G1-S transition control, significantly correlates with
poor prognosis for GBC patients (39). To ascertain how cyclin
D1 affects clinical outcome, p27Kip1 was introduced into this
study. The postoperative survival rate was greatest in patients
with no abnormality in either cyclin D1 or p27Kip1 expression,
followed by a significant decrease in those with aberrant ex-
pression of one of the two proteins, and was even lower in those
with concurrent abnormalities in both proteins (Fig. 3). These
data suggest that cyclin D1 overexpression, together with re-
duced p27Kip1 expression, affects the clinical course of GBC.
In conclusion, cyclin D1 overexpression is an early event in
gallbladder carcinogenesis and independently predicts poor
prognosis for patients with resectable GBC.
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